New drug combo aims to restore blood cells in severe anemia
NCT ID NCT07297550
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called golidocitinib, combined with strong immune-suppressing therapy, for people with severe aplastic anemia—a condition where the bone marrow stops making enough blood cells. The trial has two parts: first, it checks safety in patients who didn't improve with standard treatment; then, it tests how well the drug works in newly diagnosed patients. Up to 42 participants will take golidocitinib capsules daily or every other day, and doctors will monitor side effects and blood cell recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Golidocitinib (a JAK1 inhibitor drug taken as capsules)
What this could lead to
If successful, this could offer a new treatment option for severe aplastic anemia, helping patients recover healthy blood cell counts.
What could go wrong
This is an early-phase trial with only 42 participants, so results may not apply broadly. The drug may cause side effects or fail to improve blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••